ArticleCellular oncology (Dordrecht, Netherlands)2026
TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is among the most devastating malignancies worldwide, characterized by late diagnosis, rapid progression, and dismal survival rates. The discovery of reliable biomarkers for early detection and disease monitoring remains an urgent clinical need. Owing to its proximity to tumor cells and protein-rich composition, pancreatic juice represents a compelling reservoir for biomarker discovery.
methodsWe performed comprehensive proteomic profiling of pancreatic juice using mass spectrometry to uncover PDAC-associated biomarkers. The expression and prognostic relevance of candidate proteins were validated in patient-derived tumor tissues, sera, and tissue microarrays (TMAs). Functional roles were interrogated through RNA interference-mediated knockdown in PDAC cell lines and an orthotopic PANC-1 xenograft model.
resultsOur analyses revealed TBC1D23 as a previously unrecognized oncogenic driver in PDAC. TBC1D23 was markedly upregulated in pancreatic juice, tumor specimens, and patient sera, with elevated expression correlating strongly with lymphatic metastasis and inferior overall survival. Functionally, silencing TBC1D23 curtailed PDAC cell proliferation, migration, and invasion in vitro, and significantly attenuated tumor growth and peritoneal dissemination in vivo. Transcriptomic and biochemical analyses demonstrated that TBC1D23 depletion led to profound downregulation of VEGF-C, diminishing its secretion, and consequently impairing tumor-driven lymphangiogenesis. This effect was rescued by VEGF-C supplementation and abolished by the VEGFR3 inhibitor MAZ51, underscoring VEGF-C as a principal downstream effector. Mechanistically, TBC1D23 orchestrated EGFR trafficking, enhancing receptor recycling and membrane localization while suppressing lysosomal degradation, thereby sustaining EGFR/ERK signaling and driving VEGF-C upregulation.
conclusionsThese findings uncover TBC1D23 as a novel regulator of EGFR dynamics and a pivotal mediator of PDAC lymphatic metastasis. By delineating the TBC1D23/EGFR/VEGF-C signaling axis, this study not only identifies a promising biomarker for PDAC detection and prognosis but also highlights an actionable therapeutic target for intercepting metastatic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.